SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE: Form 990, tax year 2024

View the entire original 990 at ProPublica ↗

Organization: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (EIN 51-0197108)
Tax period: 2024-07-01 to 2025-06-30
Filed: 2026-05-14
IRS object ID: 202641349349310664
Schema version: 2024v5.5
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule J
Schedule K
Schedule L
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2026-05-14T15:38:39-05:00	ReturnTs
Tax Period End	2025-06-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	390859910	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	BAKER TILLY ADVISORY GROUP LP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	4747 EXECUTIVE DR SUITE 1300	AddressLine1Txt
City	SAN DIEGO	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92121	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2024-07-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	510197108	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY	BusinessNameLine1Txt
Business Name Line2	INSTITUTE	BusinessNameLine2Txt

Field	Value	IRS element (for citing)
Business Name Control	SANF	BusinessNameControlTxt
Phone	8586463100	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 NORTH TORREY PINES ROAD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	MICHAEL JONES	PersonNm
Person Title	CFO & TREASURER	PersonTitleTxt
Phone	8586463100	PhoneNum
Signature	2026-05-12	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Field	Value	IRS element (for citing)
IRS Responsible Prty Info Curr	Yes (1)	IRSResponsiblePrtyInfoCurrInd

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	LAUREN A HAVERLOCK	PreparerPersonNm
PTIN	P00545829	PTIN
Phone	8586271400	PhoneNum

Field	Value	IRS element (for citing)
Tax	2024	TaxYr
Build TS	2025-03-06 01:10:19Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	DAVID BRENNER	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 NORTH TORREY PINES ROAD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$369,613,683	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.SBPDISCOVERY.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1976	FormationYr
Legal Domicile State	CA	LegalDomicileStateCd
Activity Or Mission	WE TRANSLATE SCIENCE INTO HEALTH.	ActivityOrMissionDesc
Voting Members Governing Body	15	VotingMembersGoverningBodyCnt
Voting Members Independent	13	VotingMembersIndependentCnt
Total Employee	611	TotalEmployeeCnt
Total Volunteers	14	TotalVolunteersCnt
Total Gross UBI	$775,448	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$1,145	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$107,001,067	PYContributionsGrantsAmt
CY Contributions Grants	$100,911,209	CYContributionsGrantsAmt
PY Program Service Revenue	$669,975	PYProgramServiceRevenueAmt
CY Program Service Revenue	$781,895	CYProgramServiceRevenueAmt
PY Investment Income	$12,533,478	PYInvestmentIncomeAmt
CY Investment Income	$11,431,172	CYInvestmentIncomeAmt
PY Other Revenue	$3,067,961	PYOtherRevenueAmt
CY Other Revenue	$1,277,545	CYOtherRevenueAmt
PY Total Revenue	$123,272,481	PYTotalRevenueAmt
CY Total Revenue	$114,401,821	CYTotalRevenueAmt
PY Grants And Similar Paid	$0	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$0	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$63,300,127	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$67,796,159	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$0	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$0	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$1,758,791	CYTotalFundraisingExpenseAmt
PY Other Expenses	$47,874,465	PYOtherExpensesAmt
CY Other Expenses	$48,311,457	CYOtherExpensesAmt
PY Total Expenses	$111,174,592	PYTotalExpensesAmt
CY Total Expenses	$116,107,616	CYTotalExpensesAmt
PY Revenues Less Expenses	$12,097,889	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$1,705,795	CYRevenuesLessExpensesAmt
Total Assets BOY	$326,353,986	TotalAssetsBOYAmt
Total Assets EOY	$337,965,900	TotalAssetsEOYAmt
Total Liabilities BOY	$58,142,392	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$55,635,805	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$268,211,594	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$282,330,095	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE'S MISSION IS TO ADVANCE THE BIOMEDICAL SCIENCES BY CULTIVATING THE NEXT GENERATION OF SCIENTIFIC LEADERS, PROVIDING MEANINGFUL OPPORTUNITIES FOR RESEARCHERS OF ALL BACKGROUNDS TO LEARN, INNOVATE, AND MAKE BREAKTHROUGH DISCOVERIES THAT IMPROVE HUMAN HEALTH.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$95,573,862	ExpenseAmt
Revenue	$908,475	RevenueAmt
Desc	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE STUDIES THE TOUGHEST DISEASES. WE ARE FORWARD-LOOKING, COLLABORATIVE, FLEXIBLE AND MULTIDISCIPLINARY. WE EMBRACE DATA SCIENCE AND PROMOTE ENTREPRENEURSHIP. WE ARE CENTRAL TO A VIBRANT BIOMEDICAL COMMUNITY: LOCAL, NATIONAL AND INTERNATIONAL. WE ARE A LEADER WHOSE ACHIEVEMENTS ARE INSPIRING AND MEASURABLE.SEE SCHEDULE O FOR ADDITIONAL INFORMATION.	Desc
Total Program Service Expenses	$95,573,862	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	0	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (1)	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	0	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	0	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	0	ProfessionalFundraisingInd
Fundraising Activities	0	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	0	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	Yes (1)	TaxExemptBondsInd
Invest Tax Exempt Bonds	0	InvestTaxExemptBondsInd
Escrow Account	0	EscrowAccountInd
On Behalf Of Issuer	0	OnBehalfOfIssuerInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	Yes (1)	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	Yes (1)	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	0	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	192	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	611	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (1)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (1)	Form990TFiledInd
Foreign Financial Account	0	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	0	QuidProQuoContributionsInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	15	GoverningBodyVotingMembersCnt
Independent Voting Member	13	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	MICHAEL JONES	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	8586463100	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	10901 NORTH TORREY PINES RD	AddressLine1Txt
City	LA JOLLA	CityNm
State Abbreviation	CA	StateAbbreviationCd
ZIP	92037	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (24 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Highest Compensated EmployeeHighestCompensatedEmployeeInd
DAVID BRENNER
CEO & PRESIDENT	50.00	0.00	Yes (X)	Yes (X)	$994,322	$0	$351,204
KRISTIINA VUORI MD PHD
PROFESSOR	50.00	0.00			$602,266	$0	$63,406	Yes (X)
PETER ADAMS PHD
PROGRAM DIRECTOR	50.00	0.00			$450,347	$0	$83,900	Yes (X)
CARL WARE PHD
CENTER DIRECTOR, IIDC	50.00	0.00			$449,559	$0	$64,740	Yes (X)
MICHAEL JACKSON PHD
DRUG DISCOVERY & DEV, SR VP	50.00	0.00			$443,835	$0	$65,838	Yes (X)
JAMEY MARTH PHD
PROGRAM DIRECTOR	50.00	0.00			$399,446	$0	$68,664	Yes (X)
ROBIN RYAN
CFO & TREASURER (THRU 11/15/24)	50.00	0.00		Yes (X)	$414,770	$0	$50,661
NICHOLAS COSFORD
PROFESSOR & TRUSTEE	50.00	0.00	Yes (X)		$305,473	$0	$78,848
ADRIENNE CROWN JD
GENERAL COUNSEL & SECRETARY	50.00	0.00		Yes (X)	$313,425	$0	$48,179
MICHAEL JONES
CFO & TREASURER (AS OF OCT 2024)	50.00	0.00		Yes (X)	$67,222	$0	$5,883
DONALD KEARNS
CHAIR	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
LORI MOORE
VICE CHAIR	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
MICHAEL R CUNNINGHAM
TRUSTEE (THRU 11/1/24)	1.00	0.00	Yes (X)		$0	$0	$0
DAVID W DOWN
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
DANIEL J EPSTEIN
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
WILLIAM GERHART
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
DOUGLAS H OBENSHAIN
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
WILLIAM ROPER
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
TED ROTH
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
KAZUMI SHIOSAKI PHD
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
LONNA J WILLIAMS STOLPER
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
DAVID L SZEKERES JD
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
STUART TANZ
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
KATHERINE CHAPIN
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,440,665	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$881,323	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	151	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
DELOITTE & TOUCHE LLP
PO BOX 844708	DALLAS	TX	75284	PROFESSIONAL SERVICES	$433,527
1903 SOLUTIONS LLC
2549 EASTBLUFF DR STE 378	NEWPORT BEACH	CA	92660	NETWORKING, SECURITY, IT SERVICES	$425,572
BIODURO LLC
9601 JERONIMO RD	IRVINE	CA	92618	BIOTECHNOLOGY SERVICES	$404,003
UNIVERSAL PROTECTION SERVICE LP
PO BOX 31001-2374	PASADENA	CA	91110	BUILDING SECURITY SERVICES	$286,557
JAGGAER LLC
3020 CARRINGTON MILL BLVD STE 100	MORRISVILLE	NC	27560	PROCUREMENT SERVICES	$233,784

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	10	CntrctRcvdGreaterThan100KCnt
Government Grants	$69,435,701	GovernmentGrantsAmt
All Other Contributions	$31,475,508	AllOtherContributionsAmt
Noncash Contributions	$5,376	NoncashContributionsAmt
Total Contributions	$100,911,209	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	SHARED SERVICE REVENUE	Desc
Business	541990	BusinessCd
Total Revenue Column	$781,895	TotalRevenueColumnAmt
Related Or Exempt Func Income	$781,895	RelatedOrExemptFuncIncomeAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$781,895	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$6,290,034	TotalRevenueColumnAmt
Unrelated Business Revenue	$5,848	UnrelatedBusinessRevenueAmt
Exclusion	$6,284,186	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$216,365	TotalRevenueColumnAmt
Exclusion	$216,365	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$165,000	RealAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$165,000	RealAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$165,000	TotalRevenueColumnAmt
Exclusion	$165,000	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$260,353,000	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$255,211,862	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$5,141,138	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$5,141,138	TotalRevenueColumnAmt
Exclusion	$5,141,138	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt
RESEARCH ACTIVITIES	541700	$769,600	$769,600
SALE OF REAGENTS	541990	$93,660		$93,660
EQUIPMENT PROCEEDS	541990	$29,420		$29,420

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$3,500	TotalRevenueColumnAmt
Related Or Exempt Func Income	$3,500	RelatedOrExemptFuncIncomeAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$896,180	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$114,401,821	TotalRevenueColumnAmt
Related Or Exempt Func Income	$908,475	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$775,448	UnrelatedBusinessRevenueAmt
Exclusion	$11,806,689	ExclusionAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$1,668,689	TotalAmt
Program Services	$216,557	ProgramServicesAmt
Management And General	$1,418,689	ManagementAndGeneralAmt
Fundraising	$33,443	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$50,537,718	TotalAmt
Program Services	$40,304,124	ProgramServicesAmt
Management And General	$9,301,975	ManagementAndGeneralAmt
Fundraising	$931,619	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$3,413,569	TotalAmt
Program Services	$2,682,024	ProgramServicesAmt
Management And General	$707,734	ManagementAndGeneralAmt
Fundraising	$23,811	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$8,798,791	TotalAmt
Program Services	$6,810,223	ProgramServicesAmt
Management And General	$1,848,631	ManagementAndGeneralAmt
Fundraising	$139,937	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$3,377,392	TotalAmt
Program Services	$2,580,106	ProgramServicesAmt
Management And General	$727,583	ManagementAndGeneralAmt
Fundraising	$69,703	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$881,938	TotalAmt
Program Services	$248,022	ProgramServicesAmt
Management And General	$460,449	ManagementAndGeneralAmt
Fundraising	$173,467	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$577,767	TotalAmt
Program Services	$40,121	ProgramServicesAmt
Management And General	$537,646	ManagementAndGeneralAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$224,028	TotalAmt
Management And General	$224,028	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$1,500	TotalAmt
Management And General	$1,500	ManagementAndGeneralAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$600,112	TotalAmt
Management And General	$600,112	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$758,103	TotalAmt
Program Services	$595,376	ProgramServicesAmt
Management And General	$155,614	ManagementAndGeneralAmt
Fundraising	$7,113	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$295	TotalAmt
Program Services	$295	ProgramServicesAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$5,312,286	TotalAmt
Program Services	$4,854,687	ProgramServicesAmt
Management And General	$385,381	ManagementAndGeneralAmt
Fundraising	$72,218	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,910,820	TotalAmt
Program Services	$1,328,124	ProgramServicesAmt
Management And General	$542,389	ManagementAndGeneralAmt
Fundraising	$40,307	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$6,272,585	TotalAmt
Program Services	$5,837,695	ProgramServicesAmt
Management And General	$410,611	ManagementAndGeneralAmt
Fundraising	$24,279	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$290,772	TotalAmt
Program Services	$243,322	ProgramServicesAmt
Management And General	$43,818	ManagementAndGeneralAmt
Fundraising	$3,632	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$948,161	TotalAmt
Program Services	$597,449	ProgramServicesAmt
Management And General	$334,317	ManagementAndGeneralAmt
Fundraising	$16,395	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$962,864	TotalAmt
Program Services	$896,812	ProgramServicesAmt
Management And General	$62,297	ManagementAndGeneralAmt
Fundraising	$3,755	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$5,621,560	TotalAmt
Program Services	$5,235,921	ProgramServicesAmt
Management And General	$363,715	ManagementAndGeneralAmt
Fundraising	$21,924	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$231,487	TotalAmt
Management And General	$231,487	ManagementAndGeneralAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
SCIENTIFIC COLLABORATIO	$13,371,531	$13,371,531
RESARCH SUPPLIES & SERV	$9,114,792	$9,114,792
RECRUITMENT	$368,062	$279,904	$86,483	$1,675
TUITION FEES	$135,017	$135,017

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$727,777	TotalAmt
Program Services	$201,760	ProgramServicesAmt
Management And General	$330,504	ManagementAndGeneralAmt
Fundraising	$195,513	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$116,107,616	TotalAmt
Program Services	$95,573,862	ProgramServicesAmt
Management And General	$18,774,963	ManagementAndGeneralAmt
Fundraising	$1,758,791	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$3,821,604	BOYAmt
EOY	$5,236,152	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$573	BOYAmt
EOY	$273	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$7,689,710	BOYAmt
EOY	$7,794,777	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$525,718	BOYAmt
EOY	$916,882	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
EOY	$8,045	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$5,645,175	BOYAmt
EOY	$6,299,836	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$372,410	BOYAmt
EOY	$435,126	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$9,857,014	BOYAmt
EOY	$9,375,998	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$171,777,279	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$122,622,218	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$51,313,137	BOYAmt
EOY	$49,155,061	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$201,913,843	BOYAmt
EOY	$209,292,707	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$44,462,501	BOYAmt
EOY	$49,380,805	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$752,301	BOYAmt
EOY	$70,238	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$326,353,986	BOYAmt
EOY	$337,965,900	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$14,624,878	BOYAmt
EOY	$18,458,990	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$5,645,487	BOYAmt
EOY	$4,533,791	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$34,979,693	BOYAmt
EOY	$30,553,769	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$2,892,334	BOYAmt
EOY	$2,089,255	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$58,142,392	BOYAmt
EOY	$55,635,805	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$200,481,486	BOYAmt
EOY	$216,428,889	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$67,730,108	BOYAmt
EOY	$65,901,206	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$268,211,594	BOYAmt
EOY	$282,330,095	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$326,353,986	BOYAmt
EOY	$337,965,900	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$1,705,795	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$15,824,296	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$111,444,313	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$82,047,252	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$104,423,511	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$107,001,067	CurrentTaxYearMinus1YearAmt
Current Tax Year	$100,911,209	CurrentTaxYearAmt
Total	$505,827,352	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$111,444,313	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$82,047,252	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$104,423,511	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$107,001,067	CurrentTaxYearMinus1YearAmt
Current Tax Year	$100,911,209	CurrentTaxYearAmt
Total	$505,827,352	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$74,132,621	SubstantialContributorsTotAmt
Public Support Total170	$431,694,731	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$5,237,546	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$7,458,720	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$9,515,640	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$8,582,975	CurrentTaxYearMinus1YearAmt
Current Tax Year	$6,671,399	CurrentTaxYearAmt
Total	$37,466,280	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus3 Years	$19,178	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$54,014	CurrentTaxYearMinus2YearsAmt
Current Tax Year	$2,145	CurrentTaxYearAmt
Total	$75,337	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$543,368,969	TotalSupportAmt
Gross Receipts Rltd Activities	$5,296,681	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.79450	PublicSupportCY170Pct
Public Support PY170	0.83620	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	0	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	0	MailingsMembersInd
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	0	GrantsOtherOrganizationsInd
Direct Contact Legislators	0	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	Yes (1)	OtherActivitiesInd
Other Activities	$1,500	OtherActivitiesAmt
Total Lobbying Expenditures	$1,500	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I-A, LINE 1:	FormAndLineReferenceDesc
Explanation	DUES TO ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES OF WHICH A PORTION IS USED FOR LOBBYING.	ExplanationTxt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$23,494,698	BeginningYearBalanceAmt
Contributions	$2,010,300	ContributionsAmt
Investment Earnings Or Losses	$2,695,743	InvestmentEarningsOrLossesAmt
Other Expenditures	$1,060,040	OtherExpendituresAmt
End Year Balance	$27,140,701	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$21,212,422	BeginningYearBalanceAmt
Contributions	$1,002,100	ContributionsAmt
Investment Earnings Or Losses	$2,217,901	InvestmentEarningsOrLossesAmt
Other Expenditures	$937,725	OtherExpendituresAmt
End Year Balance	$23,494,698	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$20,548,272	BeginningYearBalanceAmt
Contributions	$2,825	ContributionsAmt
Investment Earnings Or Losses	$1,615,074	InvestmentEarningsOrLossesAmt
Other Expenditures	$953,749	OtherExpendituresAmt
End Year Balance	$21,212,422	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$23,536,441	BeginningYearBalanceAmt
Contributions	$1,805	ContributionsAmt
Investment Earnings Or Losses	-$2,492,894	InvestmentEarningsOrLossesAmt
Other Expenditures	$497,080	OtherExpendituresAmt
End Year Balance	$20,548,272	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$19,914,852	BeginningYearBalanceAmt
Contributions	$3,687	ContributionsAmt
Investment Earnings Or Losses	$4,470,604	InvestmentEarningsOrLossesAmt
Other Expenditures	$852,702	OtherExpendituresAmt
End Year Balance	$23,536,441	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.00000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.67000	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.33000	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Land LandGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$12,758,161	OtherCostOrOtherBasisAmt
Book Value	$12,758,161	BookValueAmt

Buildings BuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$92,863,263	OtherCostOrOtherBasisAmt
Depreciation	$65,138,754	DepreciationAmt
Book Value	$27,724,509	BookValueAmt

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$53,313	OtherCostOrOtherBasisAmt
Book Value	$53,313	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$66,102,542	OtherCostOrOtherBasisAmt
Depreciation	$57,483,464	DepreciationAmt
Book Value	$8,619,078	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$49,155,061	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp (4 entries)

DescDesc	Book ValueBookValueAmt	Method ValuationMethodValuationCd
PRIVATE EQUITY LPS	$11,493,770	F
TOTAL RETURN HEDGE FUNDS	$428,555	F
SELECT EQUITY FUNDS	$30,707,392	F
HC ALTERNATIVE CREDIT OPP	$6,751,088	F

Field	Value	IRS element (for citing)
Total Book Value Securities	$49,380,805	TotalBookValueSecuritiesAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
OPERATING LEASE LIABILITIES	$70,238
FINANCE LEASE LIABILITIES	$2,019,017

Field	Value	IRS element (for citing)
Total Liability	$2,089,255	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$130,291,000	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$15,824,296	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$664,720	DonatedServicesAndUseFcltsAmt
Other Revenue	$275	OtherRevenueAmt
Revenue Not Reported	$16,489,291	RevenueNotReportedAmt
Revenue Subtotal	$113,801,709	RevenueSubtotalAmt
Investment Expenses Not Incld	$600,112	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$600,112	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$114,401,821	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$116,172,000	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$664,720	DonatedServicesUseFcltsAmt
Expenses Not Reported	$664,720	ExpensesNotReportedAmt
Expenses Subtotal	$115,507,280	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$600,112	InvestmentExpensesNotIncld2Amt
Other Expenses Not Included	$224	OtherExpensesNotIncludedAmt
Expenses Not Rpt Fincl Stmt	$600,336	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$116,107,616	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART V, LINE 4:

THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME.

PART X, LINE 2:

THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2025 AND 2024. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2025 AND 2024.

Schedule F IRS990ScheduleF

Account Activities Outside US AccountActivitiesOutsideUSGrp (5 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND)	32	PROGRAM SERVICES	EMPLOYEES ATTENDING AND OR/SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS.	$102,105
EAST ASIA AND THE PACIFIC	6	PROGRAM SERVICES	EMPLOYEES ATTENDING AND OR/SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS.	$13,780
NORTH AMERICA	1	PROGRAM SERVICES	EMPLOYEES ATTENDING AND OR/SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS.	$77
SOUTH AMERICA	1	PROGRAM SERVICES	EMPLOYEES ATTENDING AND OR/SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS.	$2,086
CENTRAL AMERICA AND THE CARIBBEAN	0	INVESTMENTS		$18,673,412

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	40	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	40	TotalEmployeeCnt
Subtotal Spent	$18,791,460	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$18,791,460	TotalSpentAmt
Transfer To Foreign Corp	Yes (1)	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (1)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE F, PART I, LINE 3:	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTISTS DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES, AS WELL AS, TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD.
SCHEDULE F, PART I, LINE 3(F):	THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F.

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
First Class Or Charter Travel	Yes (X)	FirstClassOrCharterTravelInd
Housing Allowance Or Residence	Yes (X)	HousingAllowanceOrResidenceInd
Club Dues Or Fees	Yes (X)	ClubDuesOrFeesInd
Written Policy Ref T And E Expnss	Yes (1)	WrittenPolicyRefTAndEExpnssInd
Substantiation Required	Yes (1)	SubstantiationRequiredInd
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	0	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (1)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (1)	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (9 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
DAVID BRENNER
CEO & PRESIDENT	$985,455	$0	$0	$0	$8,867	$0	$334,500	$0	$16,704	$0	$1,345,526	$0	$0	$0
KRISTIINA VUORI MD PHD
PROFESSOR	$599,404	$0	$0	$0	$2,862	$0	$34,500	$0	$28,906	$0	$665,672	$0	$0	$0
PETER ADAMS PHD
PROGRAM DIRECTOR	$347,573	$0	$100,000	$0	$2,774	$0	$34,500	$0	$49,400	$0	$534,247	$0	$0	$0
CARL WARE PHD
CENTER DIRECTOR, IIDC	$424,744	$0	$0	$0	$24,815	$0	$34,500	$0	$30,240	$0	$514,299	$0	$0	$0
MICHAEL JACKSON PHD
DRUG DISCOVERY & DEV, SR VP	$439,745	$0	$0	$0	$4,090	$0	$34,500	$0	$31,338	$0	$509,673	$0	$0	$0
JAMEY MARTH PHD
PROGRAM DIRECTOR	$393,004	$0	$0	$0	$6,442	$0	$34,500	$0	$34,164	$0	$468,110	$0	$0	$0
ROBIN RYAN
CFO & TREASURER (THRU 11/15/24)	$409,032	$0	$0	$0	$5,738	$0	$34,500	$0	$16,161	$0	$465,431	$0	$0	$0
NICHOLAS COSFORD
PROFESSOR & TRUSTEE	$301,619	$0	$0	$0	$3,854	$0	$29,502	$0	$49,346	$0	$384,321	$0	$0	$0
ADRIENNE CROWN JD
GENERAL COUNSEL & SECRETARY	$310,697	$0	$0	$0	$2,728	$0	$31,080	$0	$17,099	$0	$361,604	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART I, LINE 1A	FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. IT IS OFFERED TO EXECUTIVES AND FACULTY. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. HOUSING ALLOWANCE FOR PERSONAL USE IS OFFERED TO EXECUTIVE STAFF. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION.
PART I, LINE 4B	A RETENTION BONUS WAS SET UP FOR THE PRESIDENT AND CEO, DR. DAVID BRENNER, WHERE VESTING WILL OCCUR THE EARLIEST OF 09/14/27. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING.
PART I, LINE 7	SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED.

Schedule K IRS990ScheduleK

Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd

Issuer Name IssuerName

Field	Value	IRS element (for citing)
Business Name Line1	COUNTY OF SAN DIEGO	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Bond Issuer EIN	956000934	BondIssuerEIN
CUSIP	79742YAQ5	CUSIPNum
Bond Issued	2015-11-12	BondIssuedDt
Issue Price	$61,963,256	IssuePriceAmt
Defeased	0	DefeasedInd
On Behalf Of Issuer	0	OnBehalfOfIssuerInd
Pool Financing	0	PoolFinancingInd

Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Retired	$27,230,000	RetiredAmt
Total Proceeds	$61,963,256	TotalProceedsAmt
Issuance Costs From Proceeds	$289,386	IssuanceCostsFromProceedsAmt
Other Spent Proceeds	$61,673,870	OtherSpentProceedsAmt
Substantial Completion	2015	SubstantialCompletionYr
Refunding Tax Exempt Bonds	Yes (1)	RefundingTaxExemptBondsInd
Refunding Taxable Bonds	0	RefundingTaxableBondsInd
Final Allocation Made	Yes (1)	FinalAllocationMadeInd
Adequate Books And Rec Maint	Yes (1)	AdequateBooksAndRecMaintInd

Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Owning Bond Financed Property	0	OwningBondFinancedPropertyInd
Any Lease Arrangements	Yes (1)	AnyLeaseArrangementsInd
Mgmt Contract Bond Fincd Prop	Yes (1)	MgmtContractBondFincdPropInd
Engage Bond Counsel Contracts	Yes (1)	EngageBondCounselContractsInd
Any Research Agreements	Yes (1)	AnyResearchAgreementsInd
Engage Bond Counsel Research	Yes (1)	EngageBondCounselResearchInd
Private Bus Use By Others	0.01290	PrivateBusUseByOthersPct
Total Private Business Use	0.01290	TotalPrivateBusinessUsePct
Bond Iss Meet Prvt Sec Pymt Test	0	BondIssMeetPrvtSecPymtTestInd
Change In Use Bond Financed Prop	0	ChangeInUseBondFinancedPropInd
Procs Nonqualified Bond Remdtd	Yes (1)	ProcsNonqualifiedBondRemdtdInd

Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Form8038 T Filed	0	Form8038TFiledInd
Rebate Not Due Yet	0	RebateNotDueYetInd
Exception To Rebate	Yes (1)	ExceptionToRebateInd
No Rebate Due	0	NoRebateDueInd
Variable Rate Issue	Yes (1)	VariableRateIssueInd
Hedge Identified In Bks And Rec	0	HedgeIdentifiedInBksAndRecInd
Gross Proceeds Invested In GIC	0	GrossProceedsInvestedInGICInd
Gross Proceeds Invested	0	GrossProceedsInvestedInd
Written Proc To Monitor Reqs	Yes (1)	WrittenProcToMonitorReqsInd

Procedures Corrective Action ProceduresCorrectiveActionGrp

Field	Value	IRS element (for citing)
Bond Reference	A	BondReferenceCd
Procedures Corrective Action	Yes (1)	ProceduresCorrectiveActionInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE K, PART I:	REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012 , RESPECTIVELY.
SCHEDULE K, PART V:	FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2024.

Schedule L IRS990ScheduleL

Loans Btwn Org Interested Prsn LoansBtwnOrgInterestedPrsnGrp

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	CAMINO PHARMA	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Relationship With Org	35% CONTROLLED ENTITY OF BOARD MEMBER	RelationshipWithOrgTxt
Loan Purpose	ACCOUNTS RECEIVABLE PROGRAM ACTIVITIES SUBAWARD AGREEMENT	LoanPurposeTxt
Loan From Organization	Yes (X)	LoanFromOrganizationInd
Original Principal	$8,045	OriginalPrincipalAmt
Balance Due	$8,045	BalanceDueAmt
Default	0	DefaultInd
Board Or Committee Approval	Yes (1)	BoardOrCommitteeApprovalInd
Written Agreement	Yes (1)	WrittenAgreementInd

Field	Value	IRS element (for citing)
Total Balance Due	$8,045	TotalBalanceDueAmt

Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp

Name Of Interested NameOfInterested

Field	Value	IRS element (for citing)
Person	CAMINO PHARMA	PersonNm

Field	Value	IRS element (for citing)
Relationship Description	35% CONTROLLED ENTITY OF BOARD MEMBER	RelationshipDescriptionTxt
Transaction	$1,980,000	TransactionAmt
Transaction	PAYMENTS TO RELATED ENTITY FOR GRANT-FUNDED PROGRAM ACTIVITIES UNDER NIH AWARDS, IN WHICH BOTH THE ORGANIZATION AND THE ENTITY PARTICIPATE AS SUBRECIPIENTS. AMOUNTS REPRESENT ALLOWABLE COSTS INCURRED UNDER SUBAWARD AGREEMENTS.	TransactionDesc
Sharing Of Revenues	0	SharingOfRevenuesInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE L, PART IV, BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS:	FormAndLineReferenceDesc
Explanation	DURING THE TAX YEAR, THE ORGANIZATION MADE PAYMENTS OF APPROXIMATELY $1,980,000 TO AN ENTITY IN WHICH A CURRENT MEMBER OF THE BOARD OF DIRECTORS HOLDS AN APPROXIMATE 38.5% OWNERSHIP INTEREST. THESE PAYMENTS WERE MADE IN CONNECTION WITH GRANT-FUNDED ACTIVITIES UNDER AWARDS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH), IN WHICH BOTH THE ORGANIZATION AND THE RELATED ENTITY PARTICIPATE AS SUBRECIPIENTS. THE PAYMENTS REPRESENT ALLOWABLE COSTS INCURRED BY THE ENTITY IN CARRYING OUT ITS PORTION OF PROGRAMMATIC ACTIVITIES UNDER THE APPLICABLE SUBAWARD AGREEMENTS.THIS RELATIONSHIP WAS DISCLOSED IN THE ORGANIZATION'S AUDITED FINANCIAL STATEMENTS FOR THE PRIOR YEAR BUT WAS NOT REPORTED ON THE PRIOR YEAR FORM 990.THE BOARD MEMBER DISCLOSED THIS FINANCIAL INTEREST IN ACCORDANCE WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. THE ORGANIZATION FOLLOWS POLICIES AND PROCEDURES CONSISTENT WITH FEDERAL REGULATIONS AND SPONSOR REQUIREMENTS, INCLUDING THOSE OF THE NIH, TO IDENTIFY, MANAGE, AND MITIGATE POTENTIAL CONFLICTS OF INTEREST. THE INTERESTED BOARD MEMBER RECUSED THEMSELVES FROM ANY DELIBERATIONS OR DECISIONS RELATED TO THESE TRANSACTIONS.ALL TRANSACTIONS WERE CONDUCTED IN THE ORDINARY COURSE OF OPERATIONS AND IN ACCORDANCE WITH THE TERMS OF THE APPLICABLE GRANT AND SUBAWARD AGREEMENTS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PART III, LINE 4A:	PUBLISHED RESEARCH JULY 1, 2024-JUNE 30, 2025 CANCER RACHAEL N. MCVICAR, PHD; RABI MURAD, PHD; ELIZABETH M. KWONG, PHD; ASUKA ALVARADO; BETHANY A. GRIMMIG, PHD; RUSLAN NURYYEV: BRIAN JAMES, PHD; CHESKA M. GALAPATE; KOEN M.O. GALENKAMP, PHD; COSIMO COMMISSO, PHD; AND EVAN Y. SNYDER, MD, PHD. "A THERAPY FOR SUPPRESSING CANONICAL AND NONCANONICAL SARS-COV-2 VIRAL ENTRY AND AN INTRINSIC INTRAPULMONARY INFLAMMATORY RESPONSE." PNAS. JULY 19, 2024 PETER D. ADAMS, PHD; NIRMALYA DASGUPTA, PHD; XUE LEI, PHD; CHRISTINA HUAN SHI, PHD; ROUVEN ARNOLD, PHD; MARCOS G. TENECHE; KARL N. MILLER, PHD; ADARSH RAJESH; ANDREW DAVIS; VALESCA ANSCHAU, PHD; ALEXANDRE R. CAMPOS; AARON HAVAS, PHD; SHANSHAN YIN, PHD; ZONG MING CHUA; TIANHUI LIU; JESSICA PROULX, PHD; MICHAEL ALCARAZ; AND KEVIN Y. YIP, PHD; AND OTHERS. "HISTONE CHAPERONE HIRA, PROMYELOCYTIC LEUKEMIA (PML) PROTEIN AND P62/SQSTM1 COORDINATE TO REGULATE INFLAMMATION DURING CELL SENESCENCE." MOLECULAR CELL. AUGUST 22, 2024 HANXIAO ZHANG; CHENYU ZHOU; ZARITH MOHAMMAD; JIANHUA ZHAO, PHD. "STRUCTURAL BASIS OF HUMAN 20S PROTEASOME BIOGENESIS." NATURE COMMUNICATIONS. SEPTEMBER 18, 2024 KEVIN THARP, PHD. "HAVE PLASTIC CULTURE MODELS PREVENTED THE DISCOVERY OF EFFECTIVE CANCER THERAPEUTICS?" BRITISH JOURNAL OF PHARMACOLOGY. NOVEMBER 3, 2024 CARL WARE, PHD, AND COLLEAGUES. "TARGETING THE TNF AND TNFR SUPERFAMILIES IN AUTOIMMUNE DISEASE AND CANCER." NATURE REVIEWS DRUG DISCOVERY. OCTOBER 24, 2024 ELENA B. PASQUALE, PHD, WITH COLLEAGUES ELSEWHERE. "FREQUENT EPHA2 RECEPTOR MUTATIONS IN CHOLANGIOCARCINOMA DISRUPT RECEPTOR FORWARD SIGNALING SUPPORTING A TUMOR SUPPRESSOR ROLE." BIOCHEMICA ET BIOPHYSICA ACTA. FEBRUARY 28, 2025 COSIMO COMMISSO, PHD, GUILLEM LAMBIES BARJAU, PHD, AND COLLEAGUES. "CELL POLARITY PROTEINS PROMOTE MACROPINOCYTOSIS IN RESPONSE TO METABOLIC STRESS." NATURE COMMUNICATIONS. DECEMBER 3, 2024 SANJU SINHA, PHD, AND COLLEAGUES. "CHARTING THE TRANSCRIPTOMIC LANDSCAPE OF PRIMARY AND METASTATIC CANCERS IN RELATION TO THEIR ORIGIN AND TARGET NORMAL TISSUES." SCIENCE ADVANCES. DECEMBER 6, 2024 ANINDYA BAGCHI, PHD, WITH COLLEAGUES ELSEWHERE. "A FORWARD GENETIC SCREEN IDENTIFIES POTASSIUM CHANNEL ESSENTIALITY IN SHH MEDULLOBLASTOMA MAINTENANCE." DEVELOPMENTAL CELL. JANUARY 2025 DEBANJAN DHAR, PHD; SOURADIPTA GANGULY, PHD; MARCOS G. TENECHE, PHD; PETER D. ADAMS, PHD, WITH COLLEAGUES ELSEWHERE. "FBP1 CONTROLS LIVER CANCER EVOLUTION FROM SENESCENT MASH HEPATOCYTES." NATURE. JANUARY 1, 2025 REMA IYER, PHD; ANIRUDDHA J. DESHPANDE, PHD, WITH COLLEAGUES ELSEWHERE. "DE NOVO DESIGN OF PEPTIDE BINDERS TO CONFORMATIONALLY DIVERSE TARGETS WITH CONTRASTIVE LANGUAGE MODELING." SCIENCE ADVANCES. JANUARY 22, 2025 ROBERT ARDECKY, PHD, AND STEVEN H. OLSON, PHD, WITH COLLEAGUES ELSEWHERE. "STRUCTURE-ACTIVITY RELATIONSHIPS OF THIADIAZOLE AGONISTS OF THE HUMAN SECRETIN RECEPTOR." SLAS DISCOVERY. AUGUST 7, 2024 EDUARD SERGIENKO, PHD, MERVE DEMIR, PHD, LAURA KOEPPING, LYNN FUJIMOTO, ANDREY A. BOBKOV, PHD, AND JIANHUA ZHAO, PHD, WITH COLLEAGUES ELSEWHERE. "STRUCTURAL BASIS FOR SUBSTRATE BINDING, CATALYSIS AND INHIBITION OF CANCER TARGET MITOCHONDRIAL CREATINE KINASE BY A COVALENT INHIBITOR." STRUCTURE. JANUARY 27, 2025 LUTZ TAUTZ, PHD, JIANQIAN WU, MAREK R. BARANOWSKI, ALEXANDER E. ALESHIN, LESTER J. LAMBERT, PHD, LAURENT J.S. DEBACKER, YE NA HAN, RANAJIT DAS, PHD, DOUGLAS J. SHEFFLER, PHD, ANDREY A. BOBKOV, PHD, AND NICHOLAS COSFORD, PHD, WITH COLLEAGUES ELSEWHERE. "FRAGMENT SCREENING IDENTIFIES NOVEL ALLOSTERIC BINDERS AND BINDING SITES IN THE VHR (DUSP3) PHOSPHATASE." ACS OMEGA. JANUARY 31, 2025 PETER D. ADAMS, PHD, AND COLLEAGUES. "P53 ENHANCES DNA REPAIR AND SUPPRESSES CYTOPLASMIC CHROMATIN FRAGMENTS AND INFLAMMATION IN SENESCENT CELLS." NATURE COMMUNICATIONS. MARCH 5, 2025 SANJU SINHA, PHD, WITH COLLEAGUES ELSEWHERE. "PRODE RECOVERS ESSENTIAL AND CONTEXT-ESSENTIAL GENES THROUGH NEIGHBORHOOD-INFORMED SCORES." GENOME BIOLOGY. FEBRUARY 2025 XUEQIN SUN, PHD, AND LAURENCE HADDADIN. "STEM CELLS IN CANCER: FROM MECHANISMS TO THERAPEUTIC STRATEGIES." REVIEW. CELLS. APRIL 3, 2025 BROOKE EMERLING, PHD, ALICIA LLORENTE, PHD, GURPREET K. ARORA, PHD, AND RABI MURAD, PHD. "PHOSPHOINOSITIDE KINASES IN CANCER: FROM MOLECULAR MECHANISMS TO THERAPEUTIC OPPORTUNITIES." NATURE REVIEWS CANCER. APRIL 3, 2025 KELLY KERSTEN, PHD, WITH COLLEAGUES ELSEWHERE. "TUMOR CELL HETEROGENEITY DRIVES SPATIAL ORGANIZATION OF THE INTRATUMORAL IMMUNE RESPONSE." JOURNAL OF EXPERIMENTAL MEDICINE. APRIL 1, 2025 LUCAS CHAVEZ, PHD, WITH COLLEAGUES ELSEWHERE. "CHROMATIN MODIFICATION ABNORMALITIES BY CHD7 AND KMT2C LOSS PROMOTE MEDULLOBLASTOMA PROGRESSION." CELL REPORTS. MAY 27, 2025 ROBERT J. WECHSLER-REYA, PHD, WITH COLLEAGUES ELSEWHERE. "ISOCITRATE DEHYDROGENASE 1 PRIMES GROUP-3 MEDULLOBLASTOMAS FOR CUPROPTOSIS." CANCER CELL. MAY 12, 2025 KEVIN YIP, PHD, WITH COLLEAGUES ELSEWHERE. "AUTOPHAGY IS AN UPSTREAM MEDIATOR OF CHROMATIN DYNAMICS IN NORMAL AND AUTOIMMUNE GERMINAL CENTRE B CELLS." JOURNAL OF CLINICAL INVESTIGATION. MAY 15, 2025 ANDREI L. OSTERMAN, PHD, WITH COLLEAGUES ELSEWHERE. "THE CELL-PERMEABLE IRON CHELATOR M606 INHIBITS MYCN-DRIVEN NEUROBLASTOMA VIA AN E2F3-MEDIATED RESPONSE." PNAS. JUNE 10, 2025 YU XIN (WILL) WANG, PHD, WITH COLLEAGUES ELSEWHERE. "MULTIOMIC PROFILING REVEALS THAT PROSTAGLANDIN E2 REVERSES AGED MUSCLE STEM CELL DYSFUNCTION, LEADING TO INCREASED REGENERATION AND STRENGTH." CELL STEM CELL. JUNE 10, 2025 CARDIOVASCULAR AND MUSCULAR DISEASES KAREN OCORR, PHD; CHRISTIANI DONDI, PHD; GEORG VOGLER, PHD; ANJALI GUPTA, PHD; STANLEY M. WALLS, ANAIS KERVADEC, PHD; MICHAELA R. ROMERO; SODA B. DIOP, PHD; ALEXANDRE R. COLAS, PHD; ROLF BODMER, PHD; AND OTHERS. "THE NUTRIENT SENSOR CRTC & SARCALUMENIN / THINMAN REPRESENT A NEW PATHWAY IN CARDIAC HYPERTROPHY." CELL REPORTS. AUGUST 27, 2024 ALESSANDRA SACCO, PHD, ALESSANDRA CECCHINI, PHD, WITH COLLEAGUES ELSEWHERE. "TENASCIN-C FROM THE TISSUE MICROENVIRONMENT PROMOTES MUSCLE STEM CELL MAINTENANCE AND FUNCTION THROUGH ANNEXIN A2." COMMUNICATIONS BIOLOGY. NOVEMBER 1, 2024 AHMED I. MAHMOUD, PHD, WITH HESHAM A. SADEK. "LEVERAGING TRANSCRIPTIONAL READOUTS AS A PLATFORM FOR DRUG REPURPOSING IN CARDIOMYOPATHY." CIRCULATION. MAY 20, 2025 JOSE LUIS MILLAN, PHD, WITH COLLEAGUES ELSEWHERE. "DENTOALVEOLAR DEFECTS AND IMPAIRED ALVEOLAR BONE HEALING IN A NEURAL CREST DIRECTED CONDITIONAL KNOCKOUT MOUSE MODEL OF HYPOPHOSPHATASIA." BONE. MAY 19, 2025 NEUROLOGIC DISEASES JEROLD CHUN, MD, PHD, AND CHRISTINE S. LIU, PHD. "ISOSEQL: COMPARING LONG-READ ISOFORMS ACROSS MULTIPLE DATASETS." BIOINFORMATICS. DECEMBER 26, 2025. SU-CHUN ZHANG, MD, PHD, SAKTHIKUMAR MATHIVANAN, PHD, WITH COLLEAGUES ELSEWHERE. "THE INTERMEDIATE FILAMENT PROTEIN GFAP REGULATES MITOCHONDRIAL FISSION IN ASTROCYTES." PNAS. DECEMBER 2, 2025. ELENA B. PASQUALE, PHD; MIKE MATSUMOTO; MARICEL GOMEZ-SOLER, PHD, AND COLLEAGUES. "MISSENSE MUTATIONS OF THE EPHRIN RECEPTOR EPHA1 ASSOCIATED WITH ALZHEIMER'S DISEASE DISRUPT RECEPTOR SIGNALING FUNCTIONS." JOURNAL OF BIOLOGICAL CHEMISTRY. FEBRUARY 2025 JEROLD CHUN, MD, PHD, AND SBP COLLEAGUES. "RNA ISOFORM DIVERSITY IN HUMAN NEURODEGENERATIVE DISEASES." ENEURO. DECEMBER 10, 2024 MICHAEL JACKSON, PHD, AND STEVEN H. OLSON, PHD, WITH COLLEAGUES ELSEWHERE. "BIASED ALLOSTERIC MODULATOR OF NEUROTENSIN RECEPTOR 1 REDUCES ETHANOL DRINKING AND RESPONSES TO ETHANOL ADMINISTRATION IN RODENTS." ADDICTION NEUROSCIENCE. DECEMBER 2024 STEVEN H. OLSON, PHD, AND OTHERS. "STRUCTURALLY TARGETED MUTAGENESIS IDENTIFIES KEY RESIDUES SUPPORTING -SYNUCLEIN MISFOLDING IN MULTIPLE SYSTEM ATROPHY." JOURNAL OF PARKINSON'S DISEASE. OCTOBER 17, 2024 DOUGLAS J. SHEFFLER, PHD, AND NICHOLAS COSFORD, PHD, WITH COLLEAGUES ELSEWHERE. "17-ESTRADIOL STATUS ALTERS NMDAR FUNCTION AND ANTIPSYCHOTIC-LIKE ACTIVITY IN FEMALE RATS." MOLECULAR PSYCHIATRY. APRIL 7, 2025 RABI MURAD, PHD, WITH COLLEAGUES ELSEWHERE. "PPAR GENETIC DELETION REVEALS GLOBAL TRANSCRIPTIONAL CHANGES IN THE BRAIN AND EXACERBATES CEREBRAL INFARCTION IN A MOUSE MODEL OF STROKE." INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. APRIL 25, 2025 JEROLD CHUN, MD, PHD, JULIET NICODEMUS AND COLLEAGUES AT SANFORD BURNHAM PREBYS. "SEQUENCE DIVERSITY AND ENCODED ENZYMATIC DIFFERENCES OF MONOCISTRONIC L1 ORF2 MRNA VARIANTS IN THE AGED NORMAL AND ALZHEIMER'S DISEASE BRAIN." JOURNAL OF NEUROSCIENCE. MAY 14, 2025 MICHAEL JACKSON, PHD, AND STEVE OLSON, PHD, WITH COLLEAGUES ELSEWHERE. "ARRESTIN-BIASED ALLOSTERIC MODULATOR OF NEUROTENSIN RECEPTOR 1 ALLEVIATES ACUTE AND CHRONIC PAIN." CELL. MAY 15, 2025 XIAO TIAN, PHD, WITH COLLEAGUES ELSEWHERE. "EXPANDING THE LANDSCAPE OF AGING VIA ORBITRAP ASTRAL MASS SPECTROMETRY AND TANDEM MASS TAG INTEGRATION." NATURE COMMUNICATIONS. MAY 22, 2025
FORM 990, PART III, LINE 4A (CONT):	DMITRY A. RODIONOV, PHD, AND TANIA N.N. TANWEE, WITH COLLEAGUES ELSEWHERE. "XYLANOLYTIC METABOLISM IS REGULATED BY COORDINATION OF TRANSCRIPTION FACTORS XYNR AND XYLR IN EXTREMELY THERMOPHILIC CALDICELLULOSIRUPTORALES." APPLIED AND ENVIRONMENTAL MICROBIOLOGY. JUNE 4, 2025 METABOLIC AND LIVER DISEASES DAVID BRENNER, PHD, DEBANJAN DHAR, PHD, AND SOURADIPTA GANGULY, PHD. "LIPID ASSOCIATED MACROPHAGES PROMOTION OF FIBROSIS RESOLUTION DURING MASH REGRESSION REQUIRES TREM2." PNAS. AUGUST 22, 2024 ANDREI L. OSTERMAN, PHD, AND COLLEAGUES. "A MICROBIOME-DIRECTED THERAPEUTIC FOOD FOR CHILDREN RECOVERING FROM SEVERE ACUTE MALNUTRITION." SCIENCE TRANSLATIONAL MEDICINE. OCTOBER 2, 2024 JAMEY D. MARTH, PHD, WITH COLLEAGUES ELSEWHERE. "AN ULTRASENSITIVE AND MODULAR PLATFORM TO DETECT SIGLEC LIGANDS AND CONTROL IMMUNE CELL FUNCTION." SCIENCE ADVANCES. OCTOBER 2, 2024 DMITRY A. RODIONOV, PHD, WITH COLLEAGUES ELSEWHERE. "GLYCOSIDE HYDROLASE-MEDIATED GLUCOMANNAN CATABOLISM IN SEGATELLA COPRI, A TARGET OF MICROBIOTA-DIRECTED FOODS FOR MALNOURISHED CHILDREN." PNAS. DECEMBER 2, 2025. CEDA STAMENKOVIC, CHIARA NICOLETTI, PHD, ALESSANDRA SACCO, PHD, WITH COLLEAGUES ELSEWHERE. "DIETARY METHIONINE RESTRICTION STARTED LATE IN LIFE PROMOTES HEALTHY AGING IN A SEX-SPECIFIC MANNER." SCIENCE ADVANCES. APRIL 18, 2025 JAMEY MARTH, PHD, JOHN HINTZE, PHD, ROBERT FRAUMENI, MAYANK SARASWAT, PHD, WITH COLLEAGUES ELSEWHERE. "COMPOSITIONAL AND TOPOLOGICAL DETERMINANTS OF A PHYSIOLOGICAL ASHWELL-MORELL RECEPTOR LIGAND." PNAS. APRIL 10, 2025 SOURADIPTA GANGULY, PHD, DEBANJAN DHAR, PHD, WITH COLLEAGUES ELSEWHERE. "MASH ADIPOSE TISSUE MACROPHAGES SECRETE EXTRACELLULAR VESICLES THAT ACTIVATE LIVER FIBROSIS IN OBESE MALE MICE." GASTROENTEROLOGY. APRIL 7, 2025 BOBBY NG AND HUDSON FREEZE, PHD, WITH COLLEAGUES ELSEWHERE. "BI-ALLELIC UGGT1 VARIANTS CAUSE A CONGENITAL DISORDER OF GLYCOSYLATION." AMERICAN JOURNAL OF HUMAN GENETICS. APRIL 19, 2025 HUDSON FREEZE, PHD, WITH COLLEAGUES ELSEWHERE. "SLC35A2 LOSS-OF-FUNCTION VARIANTS AFFECT GLYCOMIC SIGNATURES, NEURONAL FATE AND NETWORK DYNAMICS." BRAIN. MAY 26, 2025 INSOOK JANG, PHD, PAMELA ITKIN-ANSARI, PHD, AND RANDAL J. KAUFMAN, PHD, WITH COLLEAGUES ELSEWHERE." QUANTIFICATION OF FOLDED AND MISFOLDED PROINSULIN FORMS USING NONREDUCING SDS-PAGE AND PROINSULIN-SPECIFIC IMMUNOBLOTTING." BIO-PROTOCOL. JUNE 5, 2025 GIAU VAN VO, PHD, WITH COLLEAGUES ELSEWHERE. "HERBAL MEDICINE IN DIABETES TREATMENT: AN UPDATED STRATEGY WITH FLAVONOID COMPOUNDS IN PRECLINICAL AND CLINICAL STUDIES." CHEMISTRY & BIODIVERSITY. MAY 30, 2025. DAVID BRENNER, MD, AND ROBERT F. SCHWABE. "HEPATIC STELLATE CELLS: BALANCING HOMEOSTASIS, HEPATOPROTECTION AND FIBROGENESIS IN HEALTH AND DISEASE." NATURE REVIEWS: GASTROENTEROLOGY & HEPATOLOGY. MAY 22, 2025. DAVID BRENNER, MD, WITH SOURADIPTA GANGULY, PHD, RABI MURAD, PHD, AND COLLEAGUES ELSEWHERE. "REGULATION OF HEPATIC STELLATE CELL PHENOTYPES IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS." GASTROENTEROLOGY. MARCH 20, 2025. DEBANJAN DHAR, PHD, DAVID BRENNER, MD, WITH COLLEAGUES ELSEWHERE. "IMMUNOPATHOGENIC MECHANISMS AND IMMUNOREGULATORY THERAPIES IN MASLD." CELLULAR AND MOLECULAR IMMUNOLOGY. JUNE 10, 2025. EDUARD SERGIENKO, PHD, STEVE OLSON, PHD, AND COLLEAGUES AT THE PREBYS CENTER. "TARGETING OF A BILE ACID RECEPTOR, TAKEDA G PROTEIN RECEPTOR 5 [TGR5], BY A NOVEL FIRST-IN-CLASS COMPETITIVE ANTAGONIST, SBI-364, DIMINISHES HEPATIC AND RENAL CYSTOGENESIS IN POLYCYSTIC LIVER AND KIDNEY DISEASE." ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE. JUNE 30, 2025. OTHER ALEX ROSA CAMPOS, PHD, AND SVETLANA MAURYA, PHD, WITH COLLEAGUES ELSEWHERE. "DEEP, UNBIASED, AND QUANTITATIVE MASS SPECTROMETRY-BASED PLASMA PROTEOME ANALYSIS OF INDIVIDUAL RESPONSES TO MRNA COVID-19 VACCINE." JOURNAL OF PROTEOME RESEARCH. FEBRUARY 4, 2025 DERON R. HERR, PHD, WITH COLLEAGUES ELSEWHERE. "ELECTROGENIC STAPHYLOCOCCUS EPIDERMIDIS DIMINISHES THE ULTRAVIOLET B-INDUCED LABILE IRONS IN MOUSE SKIN." CURRENT MICROBIOLOGY. FEBRUARY 2025 ANDREY A. BOBKOV, PHD, WITH COLLEAGUES ELSEWHERE. "STRUCTURAL DIVERSITY AND OLIGOMERIZATION OF BACTERIAL UBIQUITIN-LIKE PROTEINS." STRUCTURE. APRIL 8, 2025 DERON HERR, PHD, WITH COLLEAGUES ELSEWHERE. "PROFILING ELECTRIC SIGNALS OF ELECTROGENIC PROBIOTIC BACTERIA USING SELF-ATTENTION ANALYSIS." APPLIED MICROBIOLOGY AND BIOTECHNOLOGY. APRIL 22, 2025 GAUTAM GUPTA, WITH COLLEAGUES ELSEWHERE. "MECHANISTIC INSIGHTS INTO LONG COVID: VIRAL PERSISTENCE, IMMUNE DYSREGULATION, AND MULTI-ORGAN DYSFUNCTION." COMPREHENSIVE PHYSIOLOGY. JUNE 2025. LARS PACHE, PHD, WITH COLLEAGUES ELSEWHERE. "GLOBAL SIRNA SCREEN IDENTIFIES HUMAN HOST FACTORS CRITICAL FOR SARS-COV-2 REPLICATION AND LATE STAGES OF INFECTION." PLOS BIOLOGY. JUNE 12, 2025 KEVIN YIP, PHD, WITH COLLEAGUES ELSEWHERE. "EBV-SISRNA-3 CONTRIBUTES TO THE FORMATION OF G4-ASSOCIATED R-LOOP UPSTREAM OF EBV LYTIC REPLICATION ORIGIN IN LATENTLY INFECTED CELLS." CELL & BIOSCIENCE. JUNE 27, 2025. SELECT AWARDS AND GRANTS CHUCK SPRUCK, PHD, STEVEN OLSON, PHD, AND EDUARD SERGIENKO, PHD, WERE AWARDED A 5-YEAR, $4 MILLION GRANT TO PURSUE THEIR WORK DISCOVERING POTENT SELECTIVE INHIBITORS OF THE HISTONE METHYLTRANSFERASE SUV39H1 FOR THE TREATMENT OF CANCER. NOTABLY, THE AWARD ORIGINATED WITH AN SBP LEAD DISCOVERY INITIATIVE GRANT. CAROLINE KUMSTA, PHD, RECEIVED A 5-YEAR, $2.9 MILLION GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND THE NATIONAL INSTITUTE ON AGING TO STUDY HORMETIC REGULATION OF AUTOPHAGY IN AGING. ANIRUDDHA DESHPANDE, PHD, WAS AWARDED A 3-YEAR, $1.6 MILLION GRANT FROM THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE TO STUDY HOW NORMAL AND CANCER STEM CELLS DIFFER IN THEIR EPIGENETIC STATES. HE ALSO RECEIVED A $50,000 GRANT FROM THE RALLY FOUNDATION TO INVESTIGATE CHROMATIN CONTROL OF LEUKEMIA STEM CELL IDENTITY. MARZIA SCORTEGAGNA, PHD, WAS AWARDED A 3-YEAR, $975,000 GRANT FROM THE DEPARTMENT OF THE ARMY TO STUDY HOW WHITE ADIPOSE TISSUE SURROUNDING LYMPH NODES MODULATES ANTI-MELANOMA IMMUNITY. ANNE BANG, PHD, RECEIVED A $165,000 AWARD FROM THE FOUNDATION FOR PRADER-WILLI RESEARCH TO SCREEN FOR DRUGS THAT MELIORATE SECRETORY GRANULE PHENOTYPES IN IPSC-DERIVED NEURONS OF THE GENETIC DISORDER. HUDSON FREEZE, PHD, RECEIVED A $117,000 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES TO ADVANCE HIS WORK IN CONGENITAL DISORDERS OF GLYCOSYLATION. MICHAEL JACKSON, PHD, RECEIVED A 5-YEAR, $4.5 MILLION GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF HEALTH AND HUMAN SERVICES TO PURSUE THE DISCOVERY AND OPTIMIZATION OF APOE4 CORRECTORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE. COSIMO COMMISSO, PHD, WAS AWARDED A 5-YEAR, $2.8 MILLION GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND NATIONAL CANCER INSTITUTE TO STUDY MACROPINOCYTOSIS INHIBITION AS A GLUTAMINE MIMETIC SENSITIZATION STRATEGY IN PANCREATIC CANCER. LINDA M. BRADLEY, PHD, RECEIVED A 5-YEAR, $3.4 MILLION GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF HEALTH AND HUMAN SERVICES TO INVESTIGATE REWIRING T CELL EXHAUSTION WITH IMMUNE CHECKPOINT BLOCKADE THERAPY. COSIMO COMMISSO, PHD, WAS AWARDED A 3-YEAR, $536,000 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF HEALTH AND HUMAN SERVICES TO STUDY THE AGING PANCREAS AS A PRO-IMMUNOGENIC NICHE. ANNE BANG, PHD, IS PART OF A MULTI-INSTITUTION TEAM TO RECEIVE A $12.7 MILLION GRANT FROM THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE (CIRM) TO CREATE A NEW RESEARCH CENTER AT UC SAN DIEGO TO STUDY HOW GENETICS INFLUENCE NEURODEVELOPMENT AND DISEASES LIKE AUTISM AND SCHIZOPHRENIA. ANIRUDDHA DESHPANDE, PHD, RECEIVED A 2-YEAR, $297,000 AWARD FROM THE AMERICAN CANCER SOCIETY TO INVESTIGATE RISK-ASSOCIATED "STEMNESS" ATTRIBUTES IN AMYOTROPHIC LATERAL SCLEROSIS. STEMNESS COMBINES THE ABILITY OF A CELL TO PERPETUATE ITS LINEAGE, TO GIVE RISE TO DIFFERENTIATED CELLS, AND TO INTERACT WITH ITS ENVIRONMENT TO MAINTAIN A BALANCE BETWEEN QUIESCENCE, PROLIFERATION, AND REGENERATION. SU-CHUN ZHANG, MD, PHD, RECEIVED A 2-YEAR, $1.2 MILLION GRANT FROM THE UNIVERSITY OF WISCONSIN-MADISON TO STUDY HOW TRISOMY 21 ALTERS HUMAN CORTICAL DEVELOPMENT AND NEURAL PLASTICITY. ANNE BANG, PHD, WAS AWARDED A 2-YEAR, $341,000 GRANT FROM UES, INC. TO SUPPORT FURTHER DEVELOPMENT OF HUMAN CELL-BASED PREDICTIVE METHODS OF NEUROTOXICITY. ALICIA LLORENTE LOPEZ, PHD, RECEIVED A 2-YEAR AMERICAN CANCER SOCIETY POSTDOCTORAL FELLOWSHIP FOR $148,000 TO EXPLORE PI5P4KG AS A NOVEL MOLECULAR VULNERABILITY OF THERAPY-RESISTANT BREAST CANCER. AMBROISE EDOUARD MANCEAU, PHD, RECEIVED AN ACS 2-YEAR FELLOWSHIP FOR $217,000 TO HELP ESTABLISH THE THERAPEUTIC POTENTIAL OF TARGETING ATP2B1/4 IN PANCREATIC CANCER.
FORM 990, PART III, LINE 4A (CONT):	PIER LORENZO PURI, MD, WAS AWARDED A 1-YEAR, $137,000 GRANT FROM THE JAIN FOUNDATION TO HELP CREATE A SINGLE CELL GENE EXPRESSION ATLAS OF DYSFERLIN-DEFICIENT MUSCLES. DEFICIENCY IN THE DYSFERLIN PROTEIN IS DUE TO A RARE, INHERITED DISORDER CHARACTERIZED BY MUSCLE WEAKNESS AND WASTING. JIANHUA ZHAO, PHD, WAS RECEIVED A $97,000 PILOT GRANT FROM THE NIH/DHHS TO PURSUE DEVELOPMENT OF A SPECIFIC PROTEASE SS18-SSX FUSIONS IN SYNOVIAL SARCOMA. VALERIA GUGLIELMI, PHD, A POSTDOCTORAL ASSOCIATE IN MAXIMILIAN D'ANGELO'S LAB RECEIVED A ONE-YEAR, $25,000 SEED GRANT FROM THE PATIENT ADVOCACY GROUP SOFT BONES TO STUDY HOW HYPOPHOSPHATASIA (HPP) ALTERS IMMUNE CELLS AND IMMUNE RESPONSE. MAXIMILIANO D'ANGELO, PHD, RECEIVED A TWO-YEAR, $297,000 DISCOVERY BOOST GRANT FROM THE AMERICAN CANCER SOCIETY TO IDENTIFY MODULATORS OF NUCLEAR PORE COMPLEX (NPC) ASSEMBLY. NPCS ARE THE CHANNELS THROUGH WHICH ALL MOLECULES PASS INTO AND OUT OF CELL NUCLEI, AND THUS CONTROL ACCESS TO THE CELL'S GENETIC INFORMATION. LUTZ TAUTZ, PHD, RECEIVED A 3-YEAR, $112,000 ADMINISTRATIVE SUPPLEMENT FROM THE NIH/DHHS FOR FRAGMENT-BASED DISCOVERY OF STEP MODULATORS IN ALZHEIMER'S DISEASE. TE XIA LOH, XXX, WAS AWARDED A 2-YEAR, $60,000 GRANT FROM THE PHRMA FOUNDATION TO INVESTIGATE OVERCOMING RESISTANCE TO PARP INHIBITION IN SMALL-CELL LUNG CANCER. BROOKE EMERLING, PHD, PATRICK KEARNEY, PHD, AND ERIC WANG, PHD, WERE AWARDED A $500,000 TARGETED GRANT TO INVESTIGATE COMPOUNDS THAT BREAK DOWN AN ENZYME REQUIRED BY THE TP53 GENE, THE MOST FREQUENTLY MUTATED GENE IN CANCERS. MICHAEL JACKSON, PHD, AND PANDURANGAN VIJAYANAND, MD, PHD, AT LA JOLLA INSTITUTE FOR IMMUNOLOGY RECEIVED A $250,000 DISCOVERY GRANT TO FURTHER LEVERAGE T CELLS TO BOOST TUMOR IMMUNE RESPONSES. STEVE OLSON, PHD, RECEIVED A $125,000 FLOWTHROUGH FUNDING AWARD FROM THE TEAM JACK FOUNDATION (VIA COLUMBIA UNIVERSITY) TO STUDY DEVELOPMENT OF A BRAIN-RESTRICTED MYC INHIBITOR FOR MEDULLOBLASTOMA. ERIC WANG, PHD, RECEIVED A 3-YEAR, $1.5 MILLION GRANT FROM THE TOBACCO-RELATED DISEASE RESEARCH PROGRAM TO OPTIMIZE SMALL MOLECULE DEGRADERS OF HELLS HELICASE TO OVERCOME PARP INHIBITOR RESISTANCE IN SCLC. ANNE BANG, PHD, WAS AWARDED A 1-YEAR, $500,000 GRANT FROM DANIEL AND PHYLLIS EPSTEIN TO DEVELOP A HUMAN-INDUCED PLURIPOTENT STEM CELL MODEL TO STUDY THE EFFECTS OF ATOMOXETINE ON NEURONAL NETWORK ACTIVITY, NEUROINFLAMMATION AND NEUROPROTECTION. ELENA PASQUALE, PHD, RECEIVED 5-YEAR, $1 MILLION AWARD FROM THE NIH/DEPART OF HEALTH AND HUMAN SERVICES TO STUDY EPHA1 HOMOTYPIC AND EPHA1-EPHA1-EPHA2 HETEROTYPIC INTERACTIONS IN CELL REGULATION. ALSO, A $27,000 AWARD FROM THE NIH/DEPART OF HEALTH AND HUMAN SERVICES TO STUDY EPH RECEPTOR HETEROINTERACTIONS IN SIGNALING. STEVEN OLSON, PHD, WAS AWARDED A 5-YEAR, $2 MILLION GRANT FROM THE NIH/DEPARTMENT OF HEALTH AND HUMAN SERVICES TO INVESTIGATE NEUROTENSIN RECEPTOR 1 AS A NOVEL TARGET FOR OPIOID USE DISORDER AND DISCOVERY OF NEW SMALL MOLECULE PROBES. ALSO, A $24,000 AWARD FROM THE IAN'S FRIENDS FOUNDATION FOR "IT'S ALL IN YOUR HEAD: BRAIN-RESTRICTED DRUGS FOR MEDULLOBLASTOMA." LINDA M. BRADLEY, PHD, RECEIVED A 2-YEAR, $478,000 AWARD FROM THE NIH/DEPARTMENT OF HEALTH AND HUMAN SERVICES TO STUDY IMMUNE CHECKPOINT BLOCKADE TARGETING THE NOVEL PSGL-1/VISTA AXIS FOR PANCREATIC CANCER. ANDREI OSTERMAN, PHD, WAS AWARDED A 5-YEAR, $1.3 MILLION GRANT FROM THE NIH/DEPARTMENT OF HEALTH AND HUMAN SERVICES TO RESEARCH GENOMIC AND METABOLOMICS FOUNDATIONS OF HUMAN-MICROBIAL SYMBIOSIS IN THE GUT. JOSE LUIS MILLAN, PHD, RECEIVED A 2-YEAR, $1.2 MILLION AWARD FROM ALETA THERAPEUTICS TO STUDY SMALL MOLECULE INHIBITOR OF ENPP1 IN THE TREATMENT OF LATE-ONSET HYPOPHOSPHATASIA. ANIRUDDHA DESHPANDE, PHD, RECEIVED A 3-YEAR, $2.3 MILLION GRANT FROM THE NIH/DHHS TO SCREEN FOR INHIBITORS OF THE CHROMATIN READER PROTEIN SGF29, WHICH PLAYS A CRUCIAL ROLE IN REGULATING GENE EXPRESSION. ANNE BANG, PHD, RECEIVED A 3-YEAR, $1.9 MILLION GRANT FROM CIRM, IN COLLABORATION WITH UC SAN DIEGO, TO MODEL THE GENETIC BASIS OF PSYCHOPATHOLOGY IN SCHIZOPHRENIA AND AUTISM. SHE WAS ALSO AWARDED A 1-YEAR, $25,000 GRANT FROM THE ALS ASSOCIATION, IN COLLABORATION WITH UC SAN DIEGO, TO CONDUCT HIGH-THROUGHPUT IMAGING SCREENING TO RESTORE TDP-43 LOCALIZATION IN AGED NEURONS. EVAN SNYDER, MD, PHD, RECEIVED A 3-YEAR, $1 MILLION GRANT FROM THE DEPARTMENT OF THE ARMY TO STUDY A CHEMICAL ENGINEERING APPROACH TO ALS THAT AMPLIFIES A MORE SOPHISTICATED VIEW OF THE MULTIMODAL THERAPEUTIC ACTIONS OF DONOR AND HOST NEURAL STEM CELLS IN THAT DISEASE. KELLY KERSTEN, PHD, RECEIVED A 3-YEAR, $255,000 GRANT FROM THE MELANOMA RESEARCH ALLIANCE TO STUDY REWIRING EXHAUSTED T CELL-DERIVED CHEMOKINES TO IMPROVE ANTI-TUMOR IMMUNITY. MAXIMILIANO D'ANGELO, PHD, RECEIVED A 1-YEAR, $97,500 AWARD FROM SANFORD BURNHAM PREBYS TO DISSECT THE ROLE OF NUP210, A NUCLEAR PORE PROTEIN, IN LEUKEMIA CELL ADHESION AND SURVIVAL. COSIMO COMMISSO, PHD, (ON BEHALF OF THE CANCER CENTER) WAS AWARDED A 2-YEAR, $8.1 MILLION CANCER CENTER SUPPORT GRANT FROM THE NATIONAL INSTITUTES OF HEALTH/DEPARTMENT OF HEALTH AND HUMAN SERVICES. THE AWARD REPRESENTS THE CENTER'S MERIT EXTENSION, AND LINKED TO OUR NCI DESIGNATION. SHEA GRENIER DAVIS, A PHD GRADUATE STUDENT IN COMMISSO'S LAB, WAS AWARDED A 3-YEAR, $122,000 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH/DEPARTMENT OF HEALTH AND HUMAN SERVICES. AHMED MAHMOUD, PHD, RECEIVED A 2-YEAR, $77,000 GRANT FROM THE NATIONAL INSTITUTES OF HEALTH/DEPARTMENT OF HEALTH AND HUMAN SERVICES TO PURSUE LABEL-FREE SINGLE-CELL IMAGING FOR QUALITY CONTROL OF CARDIOMYOCYTE BIOMANUFACTURING.
FORM 990, PART VI, SECTION B, LINE 11B	THE 990 IS PREPARED BY THE INSTITUTE'S TAX ADVISORS AND IS REVIEWED BY THE INSTITUTE'S FINANCE DEPARTMENT, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO ALL MEMBERS OF THE BOARD PRIOR TO FILING.
FORM 990, PART VI, SECTION B, LINE 12C	THE INSTITUTE REQUIRES ALL TRUSTEES, OFFICERS, MEMBERS OF COMMITTEES WITH BOARD-DELEGATED POWERS, AND EMPLOYEES TO ANNUALLY ACKNOWLEDGE RECEIPT OF THE CONFLICT OF INTEREST (COI) POLICY AND TO DISCLOSE ANY INTERESTS, RELATIONSHIPS, OR ARRANGEMENTS INCLUDING ANY MATERIAL FINANCIAL INTEREST OR RELATED PARTY TRANSACTION THAT COULD GIVE RISE TO AN ACTUAL, POTENTIAL, OR PERCEIVED CONFLICT OF INTEREST. EACH INDIVIDUAL PROVIDES A SIGNED CERTIFICATION AFFIRMING RECEIPT, REVIEW, UNDERSTANDING OF, AND AGREEMENT TO COMPLY WITH THE COI POLICY, CONSISTENT WITH RECOGNIZED GOVERNANCE BEST PRACTICES. THE INSTITUTE REVIEWS ALL DISCLOSURE STATEMENTS AND CONDUCTS A RISK ASSESSMENT TO DETERMINE WHETHER A CONFLICT OF INTEREST OR RELATED-PARTY TRANSACTION EXISTS AND WHETHER MITIGATION IS REQUIRED, INCLUDING RECUSAL OR ABSTENTION FROM DECISION-MAKING, RESTRICTION OF ACCESS TO NONPUBLIC INFORMATION, OR OTHER APPROPRIATE SAFEGUARDS. THIS REVIEW PROCESS IS ALSO DESIGNED TO HELP ENSURE THAT COMPENSATION AND OTHER ECONOMIC BENEFITS ARE REVIEWED AND APPROVED USING DISINTERESTED DECISION-MAKING AND APPROPRIATE SUPPORT SO THAT NO INDIVIDUAL RECEIVES AN IMPROPER ECONOMIC BENEFIT FROM THE INSTITUTE. WHEN AN ACTUAL OR POTENTIAL CONFLICT IS IDENTIFIED, THE MATTER IS REFERRED TO THE BOARD OF TRUSTEES OR THE APPROPRIATE BOARD DELEGATED COMMITTEE FOR REVIEW AND MANAGEMENT. INDIVIDUALS WITH A CONFLICT WITH RESPECT TO A MATTER REQUIRING BOARD OR COMMITTEE ACTION DO NOT PARTICIPATE IN DELIBERATIONS, VOTING, OR EFFORTS TO INFLUENCE THE DECISION. THE BOARD OF TRUSTEES OR COMMITTEE CONSIDERS SUCH MATTERS UNDER HEIGHTENED SCRUTINY BY DISINTERESTED TRUSTEES TO ENSURE DECISIONS ARE MADE ON AN ARM'S-LENGTH BASIS AND IN THE BEST INTERESTS OF THE INSTITUTE. DEPENDING ON THE FACTS AND CIRCUMSTANCES, THE BOARD OF TRUSTEES OR COMMITTEE MAY IMPLEMENT ADDITIONAL MANAGEMENT MEASURES, WHICH MAY INCLUDE RECUSAL FROM SPECIFIED AGENDA ITEMS, ENHANCED OVERSIGHT, USE OF INDEPENDENT COMPARABILITY DATA, OR A WRITTEN MANAGEMENT PLAN. ALL DETERMINATIONS AND RECUSAL OR ABSTENTION ACTIONS ARE DOCUMENTED IN CONTEMPORANEOUS MINUTES, AND RECORDS OF DISCLOSURES, REVIEWS, AND RESOLUTIONS ARE MAINTAINED IN ACCORDANCE WITH THE INSTITUTE'S DOCUMENT-RETENTION POLICIES.
FORM 990, PART VI, SECTION B, LINE 15	COMPENSATION FOR THE CEO/PRESIDENT AND OTHER OFFICERS IS ESTABLISHED IN ACCORDANCE WITH INSTITUTE POLICIES DESIGNED TO MEET THE IRS "REBUTTABLE PRESUMPTION OF REASONABLENESS" REQUIREMENTS UNDER TREASURY REGULATIONS 53.4958 6. AN INDEPENDENT COMPENSATION COMMITTEE, COMPOSED OF TRUSTEES WITH NO CONFLICTS OF INTEREST, REVIEWS COMPARABILITY DATA AT LEAST BIENNIALLY. THE COMMITTEE USES DATA PROVIDED BY AN EXTERNAL CONSULTANT EVALUATING COMPENSATION FROM THE INSTITUTE AND COMPARABLE ORGANIZATIONS. CONSISTENT WITH CALIFORNIA CORPORATIONS CODE 5210 AND 5231, THE BOARD DELEGATES TO THE COMMITTEE THE AUTHORITY TO REVIEW AND APPROVE COMPENSATION FOR ALL OFFICERS OTHER THAN THE CEO. THE CEO'S COMPENSATION IS REVIEWED AND APPROVED BY THE COMMITTEE AND THEN SUBMITTED TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. AS REQUIRED BY THE CALIFORNIA NONPROFIT INTEGRITY ACT, THE COMPENSATION OF THE CEO/PRESIDENT AND CFO IS REVIEWED AND APPROVED TO ENSURE IT IS "JUST AND REASONABLE." ALL DELIBERATIONS, COMPARABILITY DATA REVIEWED, COMMITTEE MEMBERS PARTICIPATING, AND THE BASIS FOR DECISIONS ARE CONTEMPORANEOUSLY DOCUMENTED IN ACCORDANCE WITH IRS SAFE HARBOR PROCEDURES. APPROVED COMPENSATION PACKAGES ARE IMPLEMENTED AND RETAINED IN THE BOARD'S WRITTEN AND ELECTRONIC RECORDS. THIS PROCESS WAS LAST DONE IN JUNE 2025. THE INSTITUTE DOES NOT HAVE ANY KEY EMPLOYEES.
FORM 990, PART VI, SECTION C, LINE 19	THE INSTITUTE MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST.